Using advanced imaging to improve treatment for pulmonary fibrosis
Official title: The role of quantitative CT and radiomic biomarkers for precision medicine in pulmonary fibrosis
Funded at University of Virginia · NIH-11019829 · Data updated 2026-11-12
This study is looking at how special CT scans and imaging features can help doctors better understand and treat patients with idiopathic pulmonary fibrosis (IPF) by predicting how the disease will progress and how well treatments might work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | February 5, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $658,368 |
| NIH project number | 5R01HL171918-02 |
| Project ID | NIH-11019829 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are undergoing treatment.
✕Less likely to help
Patients with other forms of lung disease or those not diagnosed with idiopathic pulmonary fibrosis may not benefit from this research.
What this research studies
This research investigates how quantitative CT scans and radiomic biomarkers can enhance precision medicine for patients with idiopathic pulmonary fibrosis (IPF). By analyzing high-dimensional imaging data, the study aims to identify specific characteristics of the disease that can help predict progression and response to treatment. The research builds on previous work that has generated novel molecular markers and seeks to integrate these findings with imaging data to improve clinical decision-making. Patients participating in this research may undergo additional CT scans to evaluate their disease more effectively.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for patients with pulmonary fibrosis, potentially improving their outcomes.
How similar studies have gone: Previous research has shown promise in using imaging techniques and biomarkers for similar conditions, indicating that this approach could be effective.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Noth, Imre — University of Virginia
- Study coordinator: Noth, Imre
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.